What is 64x Bio?
64x Bio is a pioneering entity in the biotechnology sector, specializing in cell line engineering. The company offers a comprehensive, end-to-end platform designed for the creation of scalable therapeutic systems. Its innovative solutions are geared towards clients in the biotechnology and pharmaceutical industries who are seeking advanced methodologies for therapeutic development. By focusing on cutting-edge technology, 64x Bio aims to significantly enhance biomanufacturing processes and support the advancement of novel therapeutic offerings.
How much funding has 64x Bio raised?
64x Bio has raised a total of $55M across 1 funding round:
Series A
$55M
Series A (2022): $55M with participation from Lifeforce Capital Gp I and Northpond Ventures
Key Investors in 64x Bio
Lifeforce Capital Gp I
Lifeforce Capital is a venture capital firm established in 2015, focusing on identifying and scaling software-driven companies within the healthcare industry.
Northpond Ventures
Northpond Ventures is an investment firm that typically backs companies in the life sciences and technology sectors, focusing on innovation and growth.
What's next for 64x Bio?
The substantial enterprise-level funding indicates that 64x Bio is poised for significant scaling and further development of its proprietary cell line engineering platform. This strategic investment will likely fuel expansion into new markets, accelerate research and development initiatives, and bolster its capacity to support a growing client base in the pharmaceutical and biotech sectors. The company's focus on scalable therapeutic systems positions it to address critical needs in biomanufacturing, potentially leading to faster and more efficient drug development pipelines.
See full 64x Bio company page
